

1

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 423 419 A1**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: **90107475.7**

(51) Int. Cl.<sup>5</sup>: **A61K 37/64, A61K 31/35,  
A61K 35/78**

(22) Date of filing: **19.04.90**

(30) Priority: **19.10.89 JP 270228/89**

(43) Date of publication of application:  
**24.04.91 Bulletin 91/17**

(84) Designated Contracting States:  
**AT BE CH DE ES FR GB IT LI LU NL SE**

(71) Applicant: **mitsui norin co., ltd.**  
**1-20, 3-chome, Nihonbashimuromachi**  
**Chuo-ku**  
**Tokyo(JP)**

(72) Inventor: **Hara, Yukihiro**  
**2-7, Minamisurugadai 2-chome**  
**Fujieda-shi, Shizuoka-ken(JP)**  
Inventor: **Honda, Miwa**  
**Urban Ellcy A-202 No.7-23 Seko 2-chome**  
**Fujieda-shi, Shizuoka-ken(JP)**

(74) Representative: **Türk, Dietmar, Dr. rer. nat.**  
**Türk, Gille + Hrabal Patentanwälte**  
**Brucknerstrasse 20**  
**W-4000 Düsseldorf 13(DE)**

(54) Inhibitive agent against activity of alpha-amylase.

(57) The effective ingredient in the inventive inhibitive agent against activity of  $\alpha$ -amylase virus is tea, e.g., black tea, or a tea polyphenol as a constituent of tea including epigallocatechin gallate, epicatechin gallate, epigallocatechin, epicatechin, (+)catechin and the isomer thereof, free theaflavin, theaflavin monogallates A and B and theaflavin digallate.

EP 0 423 419 A1

INHIBITIVE AGENT AGAINST ACTIVITY OF  $\alpha$ -AMYLASE

## BACKGROUND OF THE INVENTION

The present invention relates to a novel inhibitive agent against the activity of  $\alpha$ -amylase or, more particularly, to an inhibitive agent against the activity of  $\alpha$ -amylase with high specificity in the reaction with  $\alpha$ -amylase.

A serious problem in these days called "an age of gluttony" is that many people suffer from corpulence and an adult disease or geriatric disease as a consequence of corpulence so that dieting or control of food intake is an important means for health control. In the midst of this current, dietary fibers, which cannot be adsorbed as food, are highlighted and utilized in various aspects. The effect of dietary fibers consists in the control of the absorption of harmful substance including carcinogenic ones and enhancement of the evacuating performance of the intestines rather than positive suppression of corpulence.

$\alpha$ -Amylase is a kind of digestive enzymes capable of hydrolyzing polysaccharides and contained in the saliva and pancreatic juice of human. Accordingly, inhibition of the activity of  $\alpha$ -amylase would hopefully have an effect to prevent corpulence with adequate satisfaction of the appetite and exhibit a therapeutic effect for diabetes. Several inhibitive agents against the activity of  $\alpha$ -amylase have been developed with such an object although none of them is quite satisfactory in the activity with certain undesirable side effects in some of them.

Accordingly, it is eagerly to develop a novel inhibitive agent against activity of  $\alpha$ -amylase which can be administered to patients without particular care to undesirable side effects against human body.

## SUMMARY OF THE INVENTION

An object of the present invention is to provide a novel inhibitive agent against activity of  $\alpha$ -amylase as mentioned above. The inventor has continued extensive investigations of natural products to discover a substance capable of exhibiting the desired effect without the problems usually ensure in chemically synthesized compounds.


Thus, the inhibitive agent of the present invention against activity of  $\alpha$ -amylase comprises tea as the medicinally effective ingredient.

Further, the inhibitive agent of the invention comprises polyphenol compounds in tea as the effective ingredient. The polyphenol compound in tea as the effective ingredient in the inhibitive agent is selected from the group consisting of epigallocatechin gallate, epicatechin gallate, epigallocatechin, epicatechin, (+) catechin and the isomer thereof, free theaflavin, theaflavin monogallate A, theaflavin monogallate B and theaflavin digallate.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS


The present invention provides a novel inhibitive agent against activity of  $\alpha$ -amylase, of which tea is the effective ingredient.

The tea polyphenol compounds as the principal effective ingredients in the inventive inhibitive agent against activity of  $\alpha$ -amylase include the tea catechin compounds represented by the general formula (I) given below and the theaflavin compounds represented by the general formula (II) given below:



in which  $R_1$  is a hydrogen atom or a hydroxy group and  $R_2$  is a hydrogen atom or a 3,4,5-trihydroxy

benzoyl group; and



in which  $R_3$  and  $R_4$  are, each independently from the other, a hydrogen atom or a 3,4,5-trihydroxy benzoyl group.

Particular examples of the tea catechin compounds represented by the general formula (I) include: (-)  
 20 )epicatechin, which is a compound of the formula (I) with  $R_1 = H$  and  $R_2 = H$ ; (-)epigallocatechin, which is a compound of the formula (I) with  $R_1 = OH$  and  $R_2 = H$ ; (-)epicatechin gallate, which is a compound of the formula (I) with  $R_1 = H$  and  $R_2 = 3,4,5$ -trihydroxy benzoyl group; and (-)epigallocatechin gallate, which is a compound of the formula (I) with  $R_1 = OH$  and  $R_2 = 3,4,5$ -trihydroxy benzoyl group. Particular  
 25 examples of the theaflavin compounds include: free theaflavin, which is a compound of the formula (II) with  $R_3 = H$  and  $R_4 = H$ ; theaflavin monogallate A, which is a compound of the formula (II) with  $R_3 = 3,4,5$ -trihydroxy benzoyl group and  $R_4 = H$ ; theaflavin monogallate B, which is a compound of the formula (II) with  $R_3 = H$  and  $R_4 = 3,4,5$ -trihydroxy benzoyl group; and theaflavin digallate, which is a compound of the formula (II) with  $R_3 = 3,4,5$ -trihydroxy benzoyl group and  $R_4 = 3,4,5$ -trihydroxy benzoyl group.

The above described tea polyphenol compounds can be prepared from tea leaves as the starting  
 30 material and a method for the preparation thereof and a typical example of the product composition are described, for example, in Japanese Patent Kokai 59-219384, 60-13780 and 61-130285 and elsewhere.

When the inventive inhibitive agent against activity of  $\alpha$ -amylase is to be process into a medicament  
 form or an additive for food etc., the above described tea polyphenol as the effective ingredient as such is  
 35 admixed with the base without or with dilution with water or alcohol. In this case, the concentration thereof in the digestive tract is preferably in the range from 0.1  $\mu M$  to 5 mM or, more preferably, from 0.5  $\mu M$  to 1 mM.

The above described inhibitive agent against activity of  $\alpha$ -amylase comprises, as the effective ingre-  
 40 dient, a natural product which is a drinkable taken in daily life in a considerably large volume so that it is absolutely free from the problem of undesirable side effects against human body not only when it is used as a medicine but also when it is used as an additive of food. Moreover, the effectiveness thereof is so high that activity of  $\alpha$ -amylase can be effectively inhibited by the addition thereof even in a very low concentration to provide a means for inhibiting activity of  $\alpha$ -amylase.

In the following, examples are given to illustrate the invention in more detail.

#### 45 Example 1

The enzyme used here was a product of  $\alpha$ -amylase prepared from human saliva and supplied by Sigma Co.

50 A 150  $\mu l$  of the enzyme solution (0.44 U/ml in a buffer solution) was added to 1230  $\mu l$  of the sample solution and the mixture was incubated at 37°C for 10 minutes. Thereafter, the sample solution was admixed with 120  $\mu l$  of a solution of soluble starch as the substrate so as to have a final concentration of the substrate of 2.0 mg/ml to effect the reaction at 37°C. A 200  $\mu l$  of the solution was taken in every 3 minutes from the solution under proceeding reaction and the reducing sugar produced therein was  
 55 determined by the measurement of the absorbance at a wave-length of 540 nm according to the method of Bernfeld described in Meth. Enzymol., volume 1, page 49 (1959) by P. Bernfeld. The value of the absorbance was converted by calculation into the amount of maltose from which the reaction velocity was calculated according to the conventional procedure. The concentration of the solution for 50% inhibition of

the activity of  $\alpha$ -amylase was determined with each sample assuming that the activity of  $\alpha$ -amylase was 100% when the reaction velocity was equal to that in the control in which the same volume of the buffer solution was added in place of the sample solution. The results are shown in Table 1 below.

Table 1

Sample	Concentration for 50% inhibition
Gallic acid	$\gg 1\text{mM}$
Epicatechin	$\gg 1\text{mM}$
Isomer of epicatechin	$\gg 1\text{mM}$
Epigallocatechin	$\gg 1\text{mM}$
Isomer of epigallocatechin	$\gg 1\text{mM}$
Epicatechin gallate	$130\ \mu\text{M}$
Isomer of epicatechin gallate	$20\ \mu\text{M}$
Epigallocatechin gallate	$260\ \mu\text{M}$
Isomer of epigallocatechin gallate	$55\ \mu\text{M}$
Free theaflavin	$8\ \mu\text{M}$
Theaflavin monogallate A	$1.0\ \mu\text{M}$
Theaflavin monogallate B	$1.7\ \mu\text{M}$
Theaflavin digallate	$0.6\ \mu\text{M}$

A conclusion could be derived from the above given results that, among the catechin compounds shown in the table, epicatechin, epigallocatechin and isomers thereof have almost no power for the inhibition of the activity of  $\alpha$ -amylase but the other catechin compounds and theaflavin compounds have strong power for the inhibition of the activity of  $\alpha$ -amylase.

#### Example 2

Each of the 12-weeks old male rats of the Wistar strain, divided into a test group and a control group, was fed a high-carbohydrate diet either with or without, respectively, of 1% by weight of Polyphenon 100 which was a crude mixture of catechin compounds in a proportion shown in Table 2 below.

Table 2

Catechin compound	Polyphenon 100	
	Content, %	Relative content, %
Gallocatechin	1.44	1.6
Epigallocatechin	17.57	19.3
Catechin	-	-
Epicatechin	5.81	6.4
Epigallocatechin gallate	53.90	59.1
Epicatechin gallate	12.51	13.7
Total	91.23	100

The formulation of the high-carbohydrate diet given to the control animals was as shown below in Table 3. In the diet given to the test animals, the formulation was modified by decreasing the amount of the starch powder to 70.0% and addition of 1.0% of Polyphenon 100 instead.

Table 3

Constituent	Content in high-carbohydrate diet (control), %	Content in the diet being added Polyphenon 100, %
Casein	22.0	22.0
Salt mix	4.0	4.0
Corn oil	2.0	2.0
Vitamin complex	1.0	1.0
Starch powder	71.0	70.0
Polyphenone 100	-	1.0
Total	100	100

After 7 days of raising in this manner, the feces discharged from each animal was collected for one day and weighed to examine the change in the amount thereof caused by the addition of Polyphenon 100 to the diet. The results were that the amount in the control animals was 1.01 g per day per animal while the amount in the test animals was 1.78 g per day per animal to support the conclusion that the addition of the catechin compounds to the diet was effective to increase the amount of feces discharge. This result means that the catechin compounds act in a similar manner to dietary fibers in promoting the evacuating performance of the intestines by decreasing absorption of the carbohydrates as a consequence of the power to inhibit the activity of amylase.

#### Example 3

When the inventive inhibitive agent against the activity of  $\alpha$ -amylase is administrated to human body, the dose to be taken orally is 0.1 to 10 g per day or, preferably, 2 to 5 g per day. The form of the medicament is not particularly limitative and it can be taken as such or in the form of a powder, tablet, capsule and the like, optionally, with admixture of an extending agent. When the inventive agent is used as an additive in food, it is added to various kinds of processed food and confectionery such as breads, noodles, cakes, biscuits, cookies and the like in an amount of 0.2 to 1.0% by weight.

#### Example 4

An animal test was conducted by using ICR mice as the test animals to examine the acute toxicity of the inventive inhibitive agent against the activity of  $\alpha$ -amylase. The values of  $LD_{50}$  calculated according to the Van der Waerden method within the confidence limit were: 2412 mg/kg in the oral administration of the same crude mixture of catechin compounds as used in Example 2; 55.2 mg/kg in the intraperitoneal administration of a crude mixture of theaflavin compounds of the composition shown in Table 5 below; and 150 mg/kg in the intraperitoneal administration of epigallocatechin gallate.

Table 5

Compound	Content, %, in the crude mixture of theaflavin compounds
Free theaflavin	10.0
Theaflavin monogallate A	22.3
Theaflavin monogallate B	19.5
Theaflavin digallate	32.5
(+) Catechin	0.3
(-) Epicatechin	1.8
(-) Epigallocatechin gallate	4.7
Isomer of (-) epigallocatechin gallate	1.0
(-) Epicatechin gallate	3.9
Others (isomers of theaflavin, etc.)	4.0

#### Claims

1. An inhibitive agent against activity of  $\alpha$ -amylase which comprises tea as the effective ingredient.
2. The inhibitive agent against activity of  $\alpha$ -amylase as claimed in claim 1, wherein the effective ingredient is a tea polyphenol extracted from tea.
3. The inhibitive agent against activity of  $\alpha$ -amylase as claimed in claim 2, wherein the tea polyphenol is selected from the group consisting of epigallocatechin gallate, epicatechin gallate, epigallocatechin, epicatechin, (+)catechin and the isomer thereof, free theaflavin, theaflavin monogallate A, theaflavin monogallate B and theaflavin digallate.



European  
Patent Office

## EUROPEAN SEARCH REPORT

Application Number

EP 90 10 7475

DOCUMENTS CONSIDERED TO BE RELEVANT					
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)		
X	JOURNAL OF THE CHINESE AGRICULTURAL CHEMICAL SOCIETY vol. 27, no. 3, September 1989, TAIWAN pages 406 - 417; HA C.L. et al: "In vitro inhibition of trypsin and $\alpha$ -amylase activities by tea." * abstract * - - - -	1-3	A 61 K 37/64 A 61 K 31/35 A 61 K 35/78		
X	ARCHIVES OF ORAL BIOLOGY vol. 33, no. 11, 1988, Great Britain pages 845 - 846; KASHKET S. et al: "Inhibition of salivary amylase by water-soluble extracts of tea." * the whole document * - - - -	1-3			
L	AGRICULTURAL AND BIOLOGICAL CHEMISTRY vol. 54, no. 8, August 1990, JAPAN pages 1939 - 1945; HARA Y. et al: "The inhibition of $\alpha$ -amylase by tea polyphenols." * the whole document * - - - -	1-3			
A	US-A-4 840 966 (HARA Y. ET AL) * the whole document * - - - - -	1-3			
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)		
			A 61 K		
The present search report has been drawn up for all claims					
Place of search Berlin		Date of completion of search 29 January 91	Examiner AVEDIKIAN P.F.		
<table border="0"><tr><td><b>CATEGORY OF CITED DOCUMENTS</b> X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention</td><td><b>E: earlier patent document, but published on, or after the filing date</b> <b>D: document cited in the application</b> <b>L: document cited for other reasons</b> ..... <b>&amp;: member of the same patent family, corresponding document</b></td></tr></table>				<b>CATEGORY OF CITED DOCUMENTS</b> X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention	<b>E: earlier patent document, but published on, or after the filing date</b> <b>D: document cited in the application</b> <b>L: document cited for other reasons</b> ..... <b>&amp;: member of the same patent family, corresponding document</b>
<b>CATEGORY OF CITED DOCUMENTS</b> X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention	<b>E: earlier patent document, but published on, or after the filing date</b> <b>D: document cited in the application</b> <b>L: document cited for other reasons</b> ..... <b>&amp;: member of the same patent family, corresponding document</b>				